Posted by Michael Wonder on 26 Sep 2020
FDA grants rare paediatric disease designation to volasertib for rhabdomyosarcoma
25 September 2020 - Oncoheroes Biosciences is pleased to announce that the United States FDA has granted the designation of rare paediatric disease to volasertib, an investigational treatment for rhabdomyosarcoma.
Volasertib is an inhibitor of polo-like-kinase 1, an enzyme known to be involved in disease progression in a number of cancers.
